11:44 AM EST - Acerus Pharmaceuticals Corporation : Announced that NATESTO™ will be featured in the January 2016 issue of Andrology, the official journal of the American Society of Andrology and the European Academy of Andrology. The article, entitled “NATESTO™, a novel testosterone nasal gel, normalizes androgen levels in hypogonadal men,” highlights the positive results of the randomized, open-label, dose-ranging Phase III study and safety extension. Acerus Pharmaceuticals Corporation
shares T.ASP are trading up $0.005 at $0.13.
